Fei Ying Huang

US Patent:

7537891, May 26, 2009

Filed:

Mar 4, 2005

Appl. No.:

11/072175

Inventors:

Fei Huang - Princeton NJ, US
Xia Han - Pennington NJ, US
Karen A. Reeves - Ewing NJ, US
Lukas C. Amler - Foster City CA, US
Craig R. Fairchild - Yardley PA, US
Francis Y. Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C12Q 1/00
C12Q 1/68

US Classification:

435 6, 435 4

Abstract:

The present invention describes polynucleotides that have been discovered to correlate to the relative sensitivity or resistance of cells, e. g. , breast cell lines, to treatment with compounds that interact with and modulate, e. g. , inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e. g. , Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. Such polynucleotides comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e. g. , breast cancer, in which signaling through one or more of the aforementioned Src tyrosine and protein tyrosine kinases is involved with the disease process.

US Patent:

8492328, Jul 23, 2013

Filed:

May 15, 2008

Appl. No.:

12/600504

Inventors:

Fei Huang - Princeton NJ, US
Xia Han - Pennington NJ, US
Rameh Hafezi - Franklin Park NJ, US
Jiwen Chen - Bridgewater NJ, US
Douglas Michael Robinson - Hanover MA, US
Gayle M. Wittenberg - Princeton NJ, US
Ashok Ramesh Dongre - Newtown PA, US
Joan M. Carboni - Yardley PA, US
Ricardo M. Attar - Lawrenceville NJ, US
Warren Hurlburt - Mount Laurel NJ, US
Marco M. Gottardis - Princeton NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A01N 61/00
G01N 33/53

US Classification:

514 1, 435 71

Abstract:

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

US Patent:

20040106132, Jun 3, 2004

Filed:

Aug 26, 2003

Appl. No.:

10/648593

Inventors:

Fei Huang - Princeton NJ, US
Xia Han - Somerset NJ, US
Karen Reeves - Ewing NJ, US
Lukas Amler - Pennington NJ, US
Craig Fairchild - Yardley PA, US
Francis Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

International Classification:

C12Q001/68
C07H021/04

US Classification:

435/006000, 536/024300

Abstract:

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., breast cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, proteintyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of breast cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., breast cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

US Patent:

20060019284, Jan 26, 2006

Filed:

Jun 28, 2005

Appl. No.:

11/169041

Inventors:

Fei Huang - Princeton NJ, US
Karen Reeves - Ewing NJ, US
Xia Han - Pennington NJ, US
Craig Fairchild - Yardley PA, US
Peter Shaw - Yardley PA, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compounds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

US Patent:

20060046249, Mar 2, 2006

Filed:

Jan 17, 2003

Appl. No.:

10/501035

Inventors:

Fei Huang - Princeton NJ, US
Craig Fairchild - Yardley PA, US
Francis Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435006000, 536024100

Abstract:

The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

US Patent:

20070166704, Jul 19, 2007

Filed:

Jan 17, 2003

Appl. No.:

10/348119

Inventors:

Fei Huang - Princeton NJ, US
Craig Fairchild - Yardley PA, US
Francis Lee - Yardley PA, US
Peter Shaw - Yardley PA, US

International Classification:

C12Q 1/68
C07H 21/04

US Classification:

435006000, 536024300

Abstract:

The present invention describes polynucleotides and polypeptides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., colon cell lines, to treatment with compounds that interact with and inhibit src tyrosine kinases. These polynucleotides and polypeptides have been shown, through a weighted voting cross validation program, to have utility in predicting the intrinsic resistance and sensitivity of colon cell lines to these compounds. Such polynucleotides and polypeptides whose expression levels correlate highly with drug sensitivity or resistance comprise predictor or marker sets of polynucleotides and polypeptides that are useful in methods of predicting drug response and as prognostic or diagnostic indicators in disease management, particularly in those disease areas in which signaling through src tyrosine kinase of the src tyrosine kinase pathway is involved with the disease process.

US Patent:

20100120788, May 13, 2010

Filed:

Jan 8, 2008

Appl. No.:

12/449811

Inventors:

Fei Huang - Princeton NJ, US
Edwin A. Clark - Pennington NJ, US

International Classification:

A61K 31/496
C12Q 1/68
C12Q 1/02
C40B 20/00
G01N 33/53
A61P 35/00

US Classification:

51425219, 435 6, 435 29, 506 2, 435 71

Abstract:

The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., prostate cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of prostate cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., prostate cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

US Patent:

20120220594, Aug 30, 2012

Filed:

Oct 29, 2010

Appl. No.:

13/504498

Inventors:

Fei Huang - Princeton NJ, US
Joan Carboni - Yardley PA, US

International Classification:

A61K 31/53
A61P 35/00
C12Q 1/68

US Classification:

514243, 435 613, 435 611

Abstract:

A method for treating cancer comprising identifying a mammal that overexpresses breast cancer resistance protein; and administering to said mammal a pharmaceutical composition comprising a therapeutically effective amount of ixabepilone. In one aspect, the mammal is not administered an agent that is susceptible to breast cancer resistance protein overexpression resistance. In another aspect, the cancer is a solid tumor.